spacer
home > ict > spring 2017 > needle in a haystack
PUBLICATIONS
International Clinical Trials

Needle in a Haystack

If there is one hot zone in drug development, it is the area of rare diseases. Formerly the province of small biotechnology companies and pharmaceutical startups, this area is now attracting the attention of increasingly bigger players, as most recently exemplified by Shire’s establishment of a separate rare disease innovation hub in Cambridge, Massachusetts, US. As we have moved beyond the blockbuster era, and with the declining productivity of Big Pharma pipelines, many larger firms are looking to rare diseases as a potential alternate revenue stream – hence the increased pace of partnering and acquisition activity, as well as efforts to expand ‘organically’ into the field.

Despite the rush of entrants into the category, conducting clinical trials in this area remains a complex proposition. Much of the difficulty is derived from the fact that many rare diseases are not as well understood as more common ailments like diabetes and hypertension. The relatively small patient populations often do not easily lend themselves to defining efficacy endpoints, inclusion and exclusion criteria or other study design elements. Such a lack of clarity makes it especially difficult to devise a protocol that will meet the FDA’s scrutiny, and could even discourage people from participating.

Incentives and Challenges

Nevertheless, pharmaceutical developers have numerous motivations for conducting these studies, including Prescription Drug User Fee Act waivers, tax credits and extended exclusivity for orphan treatments; these can give companies extra time to recoup trial-associated costs. That said, many start small – initially focusing on indications with small patient populations, which may be a springboard to expanded indications or, if they are lucky, off-label usage.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Scott Treiber, PhD, MBA, is Executive Vice President of Biopharmaceutical Development at Chiltern and oversees all aspects of biopharmaceutical development including Phase 1-4 trials across a wide range of therapeutic areas. Before joining Chiltern, he held Vice President positions at Theorem, inVentiv Health, Hospira and PharmaNet. Scott is on the board of the Center for Healthcare Innovation.
spacer
Scot Treiber
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Staffordshire company Woolcool wins 2018 Queen’s Award for Innovation

The world is crying out for genuinely sustainable alternatives to manmade plastic packaging, so the winning of a Queen’s Award for Enterprise in Innovation by Staffordshire company Woolcool demonstrates the very real credibility of using a natural, renewable packaging resource – sheeps wool. First conceived by founder and CEO Angela Morris in 2001, Woolcool is a superior insulated packaging solution for the transportation of temperature-sensitive goods for the food and pharmaceutical sectors.
More info >>

White Papers

Clinical Trial Labelling – More Than Just Labels

Faubel & Co. Nachfolger GmbH

Deciding which label is best for a particular trial project is not always easy. Labels have become multifunctional tools which are able to convey variable data in different languages, indicate first opening, product originality, support ease of use or blind study drugs. They are no longer used as mere carriers of specified contents.
More info >>

 
Industry Events

HPLC 2018

29 July - 2 August 2018, Washington Marriott Wardman Park, Washington, DC, USA

Are you interested in mass spectrometry, chromatography, or electrophoresis? Are you solving complex analytical problems? Are you looking for a conference with strong scientific content, a robust program, presentations by world renowned experts, lectures by young scientists, courses offering great training opportunities, tutorials, panel discussions, vendor technical workshops, best poster competition, and a major exposition showcasing new product launches and innovative products? Mark your calendar to attend HPLC 2018 Washington, DC, the largest, most recognized international conference in the world devoted to advances in separation technologies!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement